DENVER, March 11, 2026 (GLOBE NEWSWIRE) — 247marketnews.com — In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture rounds, institutional syndicates, and aggressive capital deployment strategies. But what happens when a company advances a platform with billion-dollar potential without the backing of Silicon Valley mega-funding?
That question is increasingly being asked about Kraig Biocraft Laboratories (OTCQB: KBLB).
More than a decade ago, Kraig stood before members of the media at a press conference at the University of Notre Dame and announced that spider DNA had been successfully integrated into silkworms to produce composite fibers approaching the toughness of native spider silk. The milestone generated global interest. Hundreds of articles were written across science, industry, and mainstream media. National Geographic featured the breakthrough, and the findings were later supported by peer-reviewed publication in the Proceedings of the National Academy of Sciences.
At that moment, the science captured headlines.
What followed was not immediate commercialization, but years of stabilization, breeding continuity, and production engineering. While public attention moved on, the Company continued advancing the biological fundamentals required to transform laboratory validation into scalable output.
Capital, Media, and the Survivors
During the height of the synthetic biology funding cycle, several venture-backed companies pursuing fermentation-based spider silk raised substantial capital and secured prominent media visibility. Collectively, more than a billion dollars flowed into synthetic spider silk narratives. The capital validated the category; investors clearly recognized the transformative potential of spider silk.
What proved more difficult was manufacturability.
Despite significant funding, sustained commercial-scale structural fiber production did not materialize among several heavily capitalized entrants. Some pivoted into adjacent biomaterials. Others restructured or exited the spider silk category entirely.
Meanwhile, Kraig Labs, trading on the OTC market and advancing a complex platform built on live transgenic animals, breeding science, and industrial rearing, operated under what might be described as a complexity discount. The Company’s approach required longer development cycles and involved living biological systems that do not lend themselves to simplified narratives.
But complexity can become a moat.
The Patent Moat
Kraig’s platform is supported not only by peer-reviewed validation and biological stabilization, but also by a growing intellectual property portfolio covering transgenic silkworm technology, spider silk gene constructs, and of the resulting recombinant spider silk fibers. These patents protect both the method of producing spider silk through genetically modified silkworms and the resulting transgenic silkworms and fibers.
In a field where competitors attempted to synthetically recreate spider silk proteins outside the organism, Kraig’s biologically aligned approach is not only operationally distinct, it is also legally defensible. Intellectual property protection around both the production method and downstream materials create a structural barrier to replication, reinforcing the platform’s durability.
The science held. The breeding lines stabilized. The patents secured the platform. The production facilities expanded.
Today, coordinated deployment of approximately one million proprietary spider silk silkworm eggs across three production facilities positions the Company to target up to 10 metric tons per month of recombinant spider silk cocoons.
The Tortoise and the Race
Over the past decade, venture capital often favored speed, funding companies that promised rapid synthetic replication of spider silk proteins through fermentation platforms.
Kraig pursued a different path.
Rather than attempting to recreate spider silk in laboratory reactors, the Company focused on modifying the silkworm itself, allowing the organism’s native spinning mechanism to perform the most complex step in spider silk production: molecular alignment and fiber assembly.
Like the tortoise in a long race against better-funded competitors, the Company advanced deliberately, aligning with biology rather than attempting to circumvent it.
In materials science, physics ultimately determines viability.
And biology decides manufacturability.
Bootstrapped and Still Standing
The term “Bootstrapped Unicorn” here does not refer to current market capitalization. It reflects asymmetry.
If commercial-scale output is validated and sustained production approaches the targeted 10-ton monthly threshold, Kraig would stand as only the second confirmed commercial success in transgenic animal biotechnology history, and the first to apply that model to a biodegradable structural material.
Unicorns are often created through capital velocity.
In materials science, they are created through survivorship.
Kraig did not raise the most money. It may, however, be the last platform standing in a category that once commanded more than a billion dollars in investor enthusiasm and the only one approaching industrial-scale biological manufacturing.
Where Centuries of Infrastructure Meet Breakthrough Genetics
In biotechnology, the most scalable ideas often require the longest patience. When breakthrough genetics meets historical infrastructure, progress can accelerate rapidly. Sericulture, the cultivation of silkworms for fiber production, has existed for more than a thousand years, creating an industrial framework that few emerging materials platforms can match.
By combining that historical infrastructure with modern gene-editing science, Kraig Biocraft Laboratories may have positioned itself at a rare convergence point. If the Company’s production ramp unfolds as planned, the industry may soon witness what happens when centuries of infrastructure meet a breakthrough technology at the finish line.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5fb60b82-3d37-44e5-8283-580b937866f3
